Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 7/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24816745 | 1.00 | QPCT (0.38) | QPCTBRD4CREBBP | |
| SCHEMBL25707247 | 0.89 | QPCT (0.39) | QPCTBRD4CREBBP | |
| SCHEMBL30166786 | 0.89 | QPCT (0.39) | QPCTBRD4CREBBP | |
| SCHEMBL24813956 | 0.89 | QPCT (0.39) | QPCTBRD4CREBBP | |
| SCHEMBL30166772 | 0.88 | BRD4 (0.34) | BRD4CREBBP | |
| SCHEMBL24815415 | 0.88 | BRD4 (0.34) | BRD4CREBBP | |
| SCHEMBL24813939 | 0.88 | BRD4 (0.34) | BRD4CREBBP | |
| SCHEMBL24814387 | 0.88 | BRD4 (0.34) | BRD4CREBBP | |
| SCHEMBL30166871 | 0.88 | BRD4 (0.34) | BRD4CREBBP | |
| SCHEMBL30166842 | 0.85 | QPCT (0.37) | QPCTBRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118019737-A | Beta-lactam derivatives for the treatment of diseases | 英矽智能科技知识产权有限公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-4359405-A1 | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | Insilico Medicine IP Limited (HK) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022268179-A1 | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | INSILICO MEDICINE IP LIMITED (CN) | 2022-12-29 | — | — | WO | disclosed |